Characteristics of severe asthma patients on biologics: a real-life European registry study

BACKGROUND: The use of anti-interleukin-5 (IL5) for severe asthma is based on criteria from randomised controlled trials (RCTs), but in real-life patients might not fulfil the eligibility criteria but may benefit from biologics. We aimed to characterise patients starting anti-IL5(R) in Europe and ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Principe, Stefania, Richards, Levi B., Hashimoto, Simone, Kroes, Johannes Anthon, Van Bragt, Job J.M.H., Vijverberg, Susanne J., Sont, Jacob K., Scichilone, Nicola, Bieksiene, Kristina, Ten Brinke, Anneke, Csoma, Zsuzsanna, Dahlén, Barbro, Gemicioglu, Bilun, Grisle, Ineta, Kuna, Piotr, Lazic, Zorica, Mihaltan, Florin, Popović-Grle, Sanja, Škrgat, Sabina, Marcon, Alessandro, Caminati, Marco, Djukanovic, Ratko, Porsbjerg, Celeste, Maitland Van Der Zee, Anke-Hilse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152256/
https://www.ncbi.nlm.nih.gov/pubmed/37143845
http://dx.doi.org/10.1183/23120541.00586-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152256/
https://www.ncbi.nlm.nih.gov/pubmed/37143845
http://dx.doi.org/10.1183/23120541.00586-2022

Ejemplares similares